LEXINGTON, Mass., – November 24, 2004 – Synta Pharmaceuticals Corp., an emerging pharmaceutical company, today announced that Safi Bahcall, Ph.D., President and Chief Executive Officer, will present at the first annual Lazard Life Sciences Conference. Dr. Bahcall will provide a corporate overview and an update on the Company's clinical pipeline. The presentation will be delivered at 1:00 p.m. ET on Tuesday, November 30, 2004 from the Mandarin Oriental Hotel in New York City.
Synta Pharmaceuticals is an emerging pharmaceutical company focused on discovering, developing, and commercializing products for extending and enhancing the lives of patients with severe medical conditions. Synta has a diverse pipeline of first-in-class, small-molecule drug candidates targeting major unmet medical needs in large therapeutic markets including chronic inflammatory diseases, solid-tumor cancers, and diabetes. The Company's two lead products are in multiple Phase 2 clinical studies for chronic inflammatory diseases and cancer, respectively. All clinical candidates were developed internally, and Synta fully owns all rights in all indications and markets. Synta developed as a buy-out of a U.S. subsidiary of a large Japanese pharmaceutical company in 2002 and, as a result, has an experienced and fully integrated drug discovery and development operation. Since 2002, Synta has raised over $200 million in private financing to support its growth plans, including a recently announced $80 million round D financing. For more information, please see www.syntapharma.com.